

The Cost of 340B to Hawaii

In 2025, workers and employers lost \$48 million in negotiated rebates to 340B

Despite advocates' claims that the 340B program is free, it raises costs for patients, employers, state and local governments, Medicare, and managed Medicaid. One way it increases costs is by displacing the negotiated rebates that are used to lower net drug prices. Research by IQVIA shows that workers and employers lost \$14.5 billion in rebates nationally in 2025 due to 340B.¹ The cost to Hawaii workers and employers in 2025 was \$48 million.

Cost of 340B to Hawaii workers and employers

PER BENEFICIARY	PLAN TYPE	TOTAL COST
\$66	Private sector employees ²	\$42M
	Government employees ³	\$6M
	Total	\$48M

340B also displaces rebates in managed Medicaid, which cost Hawaii \$3M in 2025.

Cost of 340B to Hawaii managed medicaid

PER BENEFICIARY	STATE'S TOTAL COST
\$13	\$3M

The cost of 340B to Hawaii has grown substantially in recent years due to program growth. From 2023 to 2025, the number of healthcare providers prescribing 340B drugs, the number of 340B facilities, and the value of 340B drug purchases all increased.

340B growth in Hawaii: 2023 to 2025

340B PRESCRIBERS		340B FACILITIES ⁴		340B DRUG PURCHASES ⁵	
#	GROWTH	#	GROWTH	#	GROWTH
3,488	+3%	144	+1%	\$604 million	+64%

340B utilization in Hawaii is slightly higher than neighboring state but in line with national average.

Hawaii vs. neighbor

STATE	340B UTILIZATION ⁶	COST PER BENEFICIARY
HI	11%	\$66
AK	8%	\$49
Total U.S.	14%	\$81

1. The cost of 340B to states. IQVIA. 2026 (to appear).
2. Includes employer-sponsored plans and ACA health plans.
3. Includes state and local government employees.
4. Based on 340B "parent" facilities, not satellite sites or contract pharmacies.
5. 340B drug purchases at Wholesaler Acquisition Cost (WAC).
6. Percentage of 340B business by state, averaged over drug purchases and claims.